BRPI0507945A - derivados de azabiciclo (3.1.0) hexano utilizáveis como moduladores de receptores d3 de dopamina - Google Patents
derivados de azabiciclo (3.1.0) hexano utilizáveis como moduladores de receptores d3 de dopaminaInfo
- Publication number
- BRPI0507945A BRPI0507945A BRPI0507945-4A BRPI0507945A BRPI0507945A BR PI0507945 A BRPI0507945 A BR PI0507945A BR PI0507945 A BRPI0507945 A BR PI0507945A BR PI0507945 A BRPI0507945 A BR PI0507945A
- Authority
- BR
- Brazil
- Prior art keywords
- group
- alkyl
- alkoxy
- halo
- dopamine
- Prior art date
Links
- 102000004073 Dopamine D3 Receptors Human genes 0.000 title abstract 3
- 108090000525 Dopamine D3 Receptors Proteins 0.000 title abstract 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 title abstract 3
- 125000000217 alkyl group Chemical group 0.000 abstract 5
- 125000003545 alkoxy group Chemical group 0.000 abstract 3
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 3
- -1 halo C1-4 alkyl Chemical group 0.000 abstract 3
- 125000005843 halogen group Chemical group 0.000 abstract 3
- 125000002861 (C1-C4) alkanoyl group Chemical group 0.000 abstract 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 2
- 229910052736 halogen Inorganic materials 0.000 abstract 2
- 229910052739 hydrogen Inorganic materials 0.000 abstract 2
- 239000001257 hydrogen Substances 0.000 abstract 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 2
- 125000004076 pyridyl group Chemical group 0.000 abstract 2
- 125000001424 substituent group Chemical group 0.000 abstract 2
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 abstract 1
- 239000000164 antipsychotic agent Substances 0.000 abstract 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 abstract 1
- 125000002619 bicyclic group Chemical group 0.000 abstract 1
- 229910052801 chlorine Inorganic materials 0.000 abstract 1
- 239000000460 chlorine Substances 0.000 abstract 1
- 125000001309 chloro group Chemical group Cl* 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 206010013663 drug dependence Diseases 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 125000001072 heteroaryl group Chemical group 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 abstract 1
- 239000000543 intermediate Substances 0.000 abstract 1
- 125000000842 isoxazolyl group Chemical group 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 208000011117 substance-related disease Diseases 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
- 125000000335 thiazolyl group Chemical group 0.000 abstract 1
- 125000001544 thienyl group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Nutrition Science (AREA)
- Anesthesiology (AREA)
- Otolaryngology (AREA)
- Pain & Pain Management (AREA)
- Gynecology & Obstetrics (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0403990A GB0403990D0 (en) | 2004-02-23 | 2004-02-23 | Compounds |
| GB0404083A GB0404083D0 (en) | 2004-02-24 | 2004-02-24 | Compounds |
| GB0417120A GB0417120D0 (en) | 2004-07-30 | 2004-07-30 | Compounds |
| PCT/EP2005/001940 WO2005080382A1 (en) | 2004-02-23 | 2005-02-21 | Azabicyclo (3.1.0) hexane derivatives useful as modulators of dopamine d3 receptors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0507945A true BRPI0507945A (pt) | 2007-07-24 |
Family
ID=34890800
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0507945-4A BRPI0507945A (pt) | 2004-02-23 | 2005-02-21 | derivados de azabiciclo (3.1.0) hexano utilizáveis como moduladores de receptores d3 de dopamina |
Country Status (25)
| Country | Link |
|---|---|
| US (3) | US7855298B2 (https=) |
| EP (3) | EP2060570B1 (https=) |
| JP (1) | JP4960217B2 (https=) |
| KR (1) | KR101143718B1 (https=) |
| CN (1) | CN1946714B (https=) |
| AR (1) | AR047890A1 (https=) |
| AT (3) | ATE451364T1 (https=) |
| AU (2) | AU2005215918C1 (https=) |
| BR (1) | BRPI0507945A (https=) |
| CA (1) | CA2557115C (https=) |
| CY (3) | CY1109854T1 (https=) |
| DE (1) | DE602005018190D1 (https=) |
| DK (3) | DK1745040T3 (https=) |
| ES (2) | ES2380990T3 (https=) |
| HR (3) | HRP20100114T1 (https=) |
| IL (1) | IL177184A0 (https=) |
| MA (1) | MA28438B1 (https=) |
| NO (1) | NO20064309L (https=) |
| PE (1) | PE20051173A1 (https=) |
| PL (3) | PL2060570T3 (https=) |
| PT (3) | PT1745040E (https=) |
| RU (1) | RU2434011C2 (https=) |
| SI (3) | SI1745040T1 (https=) |
| TW (1) | TW200538113A (https=) |
| WO (1) | WO2005080382A1 (https=) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT1745040E (pt) * | 2004-02-23 | 2010-03-08 | Glaxo Group Ltd | Derivados do azabiciclo3.1.0-hexano úteis como moduladores dos receptores d3 da dopamina |
| US20070043100A1 (en) | 2005-08-16 | 2007-02-22 | Hagen Eric J | Novel polymorphs of azabicyclohexane |
| GB0507601D0 (en) * | 2005-04-14 | 2005-05-18 | Glaxo Group Ltd | Compounds |
| GB0507602D0 (en) | 2005-04-14 | 2005-05-18 | Glaxo Group Ltd | Compounds |
| GB0507680D0 (en) | 2005-04-15 | 2005-05-25 | Glaxo Group Ltd | Compounds |
| GB0512099D0 (en) * | 2005-06-14 | 2005-07-20 | Glaxo Group Ltd | Compounds |
| EP1891056B1 (en) | 2005-06-14 | 2010-10-13 | Glaxo Group Limited | Novel compounds |
| WO2007006117A1 (en) * | 2005-07-13 | 2007-01-18 | Nicogen Inc. | Novel cyp2a6 inhibitors |
| EP1915146A4 (en) | 2005-07-27 | 2010-06-02 | Dov Pharmaceutical Inc | NOVEL 1-ARYL-3-AZABICYCLO [3.1.0] HEXANEES. PREPARATION AND USE FOR THE TREATMENT OF NEUROPSYCHIATRIC DISEASES |
| GB0517175D0 (en) * | 2005-08-22 | 2005-09-28 | Glaxo Group Ltd | Compounds |
| GB0517187D0 (en) * | 2005-08-22 | 2005-09-28 | Glaxo Group Ltd | Compounds |
| GB0517193D0 (en) * | 2005-08-22 | 2005-09-28 | Glaxo Group Ltd | Novel use |
| US7799815B2 (en) * | 2005-08-22 | 2010-09-21 | Glaxo Group Limited | Triazole derivatives as modulators of dopamine D3 receptors |
| GB0517191D0 (en) | 2005-08-22 | 2005-09-28 | Glaxo Group Ltd | Compounds |
| EA200870404A1 (ru) | 2006-04-03 | 2009-04-28 | Глэксо Груп Лимитед | Производные азабицикло[3.1.0.]гексила в качестве модуляторов рецепторов допамина d3 |
| GB0607899D0 (en) * | 2006-04-03 | 2006-05-31 | Glaxo Group Ltd | Process for preparing heterocyclic derivatives |
| GB0703387D0 (en) * | 2007-02-21 | 2007-03-28 | Glaxo Group Ltd | Novel compounds |
| WO2007113258A1 (en) * | 2006-04-03 | 2007-10-11 | Glaxo Group Limited | Azabicyclo [3. 1. o] hexane derivatives as modulators of dopamine d3 receptors |
| EP2007751B1 (en) * | 2006-04-03 | 2013-08-21 | Glaxo Group Limited | Azabicyclo [3. 1. o] hexyl derivatives as modulators of dopamine d3 receptors |
| GB0608452D0 (en) * | 2006-04-27 | 2006-06-07 | Glaxo Group Ltd | Novel compounds |
| US20080045725A1 (en) | 2006-04-28 | 2008-02-21 | Murry Jerry A | Process For The Synthesis of (+) And (-)-1-(3,4-Dichlorophenyl)-3-Azabicyclo[3.1.0]Hexane |
| GB0616574D0 (en) * | 2006-08-21 | 2006-09-27 | Glaxo Group Ltd | Compounds |
| US8138377B2 (en) | 2006-11-07 | 2012-03-20 | Dov Pharmaceutical, Inc. | Arylbicyclo[3.1.0]hexylamines and methods and compositions for their preparation and use |
| EP2167083B1 (en) * | 2007-06-06 | 2015-10-28 | Euthymics Bioscience, Inc. | 1- heteroaryl-3-azabicyclo[3.1.0]hexanes, methods for their preparation and their use as medicaments |
| US9133159B2 (en) | 2007-06-06 | 2015-09-15 | Neurovance, Inc. | 1-heteroaryl-3-azabicyclo[3.1.0]hexanes, methods for their preparation and their use as medicaments |
| GB0719235D0 (en) | 2007-10-02 | 2007-11-14 | Glaxo Group Ltd | Novel compounds |
| GB0719234D0 (en) * | 2007-10-02 | 2007-11-14 | Glaxo Group Ltd | Novel compounds |
| MX2010014500A (es) | 2008-06-24 | 2011-05-30 | Codexis Inc | Procedimientos biocataliticos para la preparacion de compuestos de prolina biciclica fusionada sustancialmente estereomericamente puros. |
| US8536185B2 (en) * | 2008-09-22 | 2013-09-17 | Cayman Chemical Company, Incorporated | Multiheteroaryl compounds as inhibitors of H-PGDS and their use for treating prostaglandin D2 mediated diseases |
| KR20120106697A (ko) * | 2009-06-26 | 2012-09-26 | 파나세아 바이오테크 리미티드 | 신규 아자비시클로헥산 |
| US20140206740A1 (en) | 2011-07-30 | 2014-07-24 | Neurovance, Inc. | Use Of (1R,5S)-(+)-(Napthalen-2-yl)-3-Azabicyclo[3.1.0]Hexane In The Treatment Of Conditions Affected By Monoamine Neurotransmitters |
| EP3068226A4 (en) * | 2013-11-11 | 2017-05-17 | Euthymics Bioscience, Inc. | Novel methods |
| ES2821896T3 (es) | 2015-08-05 | 2021-04-28 | Indivior Uk Ltd | Antagonistas del receptor de dopamina D3 que tienen una unidad estructural biciclo |
| US11447484B2 (en) | 2018-01-26 | 2022-09-20 | Shionogi & Co., Ltd. | Cyclic compound having dopamine D3 receptor antagonistic effect |
| AU2021296163B2 (en) | 2020-06-22 | 2024-07-04 | Corcept Therapeutics Incorporated | Quaternary indazole glucocorticoid receptor antagonists |
| US12115154B2 (en) | 2020-12-16 | 2024-10-15 | Srx Cardio, Llc | Compounds for the modulation of proprotein convertase subtilisin/kexin type 9 (PCSK9) |
| IL313663A (en) | 2021-12-21 | 2024-08-01 | Corcept Therapeutics Inc | Piperazine indazole glucocorticoid receptor antagonists |
| KR20240125035A (ko) | 2021-12-21 | 2024-08-19 | 코어셉트 쎄라퓨틱스 인코포레이티드 | 이환 인다졸 글루코코르티코이드 수용체 길항제 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI274750B (en) * | 1999-01-12 | 2007-03-01 | Abbott Gmbh & Co Kg | Triazole compounds showing high affinity to dopamine D3 receptor and pharmaceutical composition comprising the same |
| GB0015562D0 (en) * | 2000-06-23 | 2000-08-16 | Pfizer Ltd | Heterocycles |
| EP1335915B1 (en) | 2000-11-14 | 2008-01-02 | Smithkline Beecham Plc | Tetrahydrobenzazepine derivatives useful as modulators of dopamine d3 receptors (antipsychotic agents) |
| US6569887B2 (en) * | 2001-08-24 | 2003-05-27 | Dov Pharmaceuticals Inc. | (−)-1-(3,4-Dichlorophenyl)-3-azabicyclo[3.1.0]hexane, compositions thereof, and uses as a dopamine-reuptake |
| EA006708B1 (ru) * | 2001-10-22 | 2006-02-24 | Пфайзер Продактс Инк. | Производные 3-азабицикло (3.1.0) гексана в качестве антагонистов опиоидного рецептора |
| WO2004014881A2 (en) * | 2002-08-09 | 2004-02-19 | Astra Zeneca Ab | '1,2,4'oxadiazoles as modulators of metabotropic glutamate receptor-5 |
| PT1745040E (pt) * | 2004-02-23 | 2010-03-08 | Glaxo Group Ltd | Derivados do azabiciclo3.1.0-hexano úteis como moduladores dos receptores d3 da dopamina |
| GB0507601D0 (en) * | 2005-04-14 | 2005-05-18 | Glaxo Group Ltd | Compounds |
| GB0507602D0 (en) | 2005-04-14 | 2005-05-18 | Glaxo Group Ltd | Compounds |
| GB0507680D0 (en) * | 2005-04-15 | 2005-05-25 | Glaxo Group Ltd | Compounds |
| EP1891056B1 (en) | 2005-06-14 | 2010-10-13 | Glaxo Group Limited | Novel compounds |
| GB0517175D0 (en) | 2005-08-22 | 2005-09-28 | Glaxo Group Ltd | Compounds |
| US7799815B2 (en) * | 2005-08-22 | 2010-09-21 | Glaxo Group Limited | Triazole derivatives as modulators of dopamine D3 receptors |
| GB0517187D0 (en) * | 2005-08-22 | 2005-09-28 | Glaxo Group Ltd | Compounds |
| GB0517191D0 (en) | 2005-08-22 | 2005-09-28 | Glaxo Group Ltd | Compounds |
| GB0517193D0 (en) * | 2005-08-22 | 2005-09-28 | Glaxo Group Ltd | Novel use |
| EA200870404A1 (ru) | 2006-04-03 | 2009-04-28 | Глэксо Груп Лимитед | Производные азабицикло[3.1.0.]гексила в качестве модуляторов рецепторов допамина d3 |
| GB0616574D0 (en) * | 2006-08-21 | 2006-09-27 | Glaxo Group Ltd | Compounds |
-
2005
- 2005-02-21 PT PT05707610T patent/PT1745040E/pt unknown
- 2005-02-21 ES ES08169935T patent/ES2380990T3/es not_active Expired - Lifetime
- 2005-02-21 DE DE602005018190T patent/DE602005018190D1/de not_active Expired - Lifetime
- 2005-02-21 EP EP08169935A patent/EP2060570B1/en not_active Expired - Lifetime
- 2005-02-21 US US10/598,200 patent/US7855298B2/en not_active Expired - Fee Related
- 2005-02-21 DK DK05707610.1T patent/DK1745040T3/da active
- 2005-02-21 DK DK08169934.0T patent/DK2070922T3/da active
- 2005-02-21 EP EP08169934A patent/EP2070922B1/en not_active Expired - Lifetime
- 2005-02-21 SI SI200530923T patent/SI1745040T1/sl unknown
- 2005-02-21 PE PE2005000205A patent/PE20051173A1/es not_active Application Discontinuation
- 2005-02-21 AT AT05707610T patent/ATE451364T1/de active
- 2005-02-21 PL PL08169935T patent/PL2060570T3/pl unknown
- 2005-02-21 AR ARP050100632A patent/AR047890A1/es not_active Application Discontinuation
- 2005-02-21 KR KR1020067016833A patent/KR101143718B1/ko not_active Expired - Fee Related
- 2005-02-21 SI SI200531503T patent/SI2060570T1/sl unknown
- 2005-02-21 JP JP2007500152A patent/JP4960217B2/ja not_active Expired - Fee Related
- 2005-02-21 TW TW094105108A patent/TW200538113A/zh unknown
- 2005-02-21 AU AU2005215918A patent/AU2005215918C1/en not_active Ceased
- 2005-02-21 PL PL05707610T patent/PL1745040T3/pl unknown
- 2005-02-21 AT AT08169935T patent/ATE542816T1/de active
- 2005-02-21 EP EP05707610A patent/EP1745040B9/en not_active Expired - Lifetime
- 2005-02-21 CA CA2557115A patent/CA2557115C/en not_active Expired - Fee Related
- 2005-02-21 AT AT08169934T patent/ATE520686T1/de active
- 2005-02-21 DK DK08169935.7T patent/DK2060570T3/da active
- 2005-02-21 CN CN2005800126155A patent/CN1946714B/zh not_active Expired - Fee Related
- 2005-02-21 PT PT08169934T patent/PT2070922E/pt unknown
- 2005-02-21 PL PL08169934T patent/PL2070922T3/pl unknown
- 2005-02-21 SI SI200531398T patent/SI2070922T1/sl unknown
- 2005-02-21 BR BRPI0507945-4A patent/BRPI0507945A/pt active Search and Examination
- 2005-02-21 WO PCT/EP2005/001940 patent/WO2005080382A1/en not_active Ceased
- 2005-02-21 ES ES05707610T patent/ES2337590T3/es not_active Expired - Lifetime
- 2005-02-21 HR HR20100114T patent/HRP20100114T1/hr unknown
- 2005-02-21 RU RU2006133909/04A patent/RU2434011C2/ru not_active IP Right Cessation
- 2005-02-21 PT PT08169935T patent/PT2060570E/pt unknown
-
2006
- 2006-07-31 IL IL177184A patent/IL177184A0/en unknown
- 2006-08-22 MA MA29286A patent/MA28438B1/fr unknown
- 2006-09-22 NO NO20064309A patent/NO20064309L/no not_active Application Discontinuation
-
2009
- 2009-09-01 AU AU2009212887A patent/AU2009212887A1/en not_active Abandoned
- 2009-12-16 US US12/639,282 patent/US8283474B2/en not_active Expired - Fee Related
- 2009-12-16 US US12/639,129 patent/US8263782B2/en not_active Expired - Fee Related
-
2010
- 2010-03-01 CY CY20101100197T patent/CY1109854T1/el unknown
-
2011
- 2011-10-26 HR HR20110781T patent/HRP20110781T1/hr unknown
- 2011-11-07 CY CY20111101073T patent/CY1112011T1/el unknown
-
2012
- 2012-03-29 HR HR20120281T patent/HRP20120281T1/hr unknown
- 2012-04-11 CY CY20121100356T patent/CY1113029T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0507945A (pt) | derivados de azabiciclo (3.1.0) hexano utilizáveis como moduladores de receptores d3 de dopamina | |
| AU2007256708B2 (en) | Organic compounds | |
| CN102388055B (zh) | 咪唑并[2,1-b][1,3,4]噻二唑衍生物 | |
| AR060237A1 (es) | Compuesto de 3-azabiciclo[3.1.0]hexano como moduladores del receptor de dopamina d3, su uso para la preparacion de un medicamento para el tratamiento de afecciones psicoticas y composicion farmaceutica que lo comprende. | |
| DE602006006850D1 (de) | Als modulatoren von dopamin-d3-rezeptoren geeignete azabicyclo-(3,1,0)-hexan-derivate | |
| BRPI0718966B8 (pt) | composto, composição farmacêutica, inibidor plk1 e agente antitumoral | |
| BR0313078A (pt) | Composto ou um sal deste farmaceuticamente aceitável, composição farmacêutica, e, uso do composto ou de um sal deste farmaceuticamente aceitável | |
| BRPI0607589A2 (pt) | derivados de imidazo [1,5-a] piridinas, o respectivo processo de preparo e as composições farmacêuticas que os contêm | |
| PT1045830E (pt) | Derivados alfa-aminoamidas uteis como agentes analgesicos | |
| BR112012013511A2 (pt) | derivados de difenil-pirazolopiridinas, sua preparação e seu uso como não moduladores do receptor nuclear | |
| MX2011011516A (es) | Compuestos farmaceuticos. | |
| CN114025847B (zh) | 作为tlr信号传导的调节剂的化合物和组合物 | |
| CY1112679T1 (el) | Κινολινες και θεραπευτικη χρηση αυτων | |
| GB0507680D0 (en) | Compounds | |
| BRPI0713951B8 (pt) | derivados de quinazolina, e composição farmacêutica | |
| DE602006004882D1 (de) | Azabicycloä3.1.0ühexylphenylderivate als modulatoren von dopamin-d3-rezeptoren | |
| GB0507601D0 (en) | Compounds | |
| PE20080191A1 (es) | Compuestos heterociclicos apropiados para tratar trastornos que responden a la modulacion del receptor de serotonina 5ht6 | |
| ME02351B (me) | Derivati 2 -oxo- 1-imidazolidinil imidazotiadiazol | |
| ATE484502T1 (de) | Neue verbindungen | |
| BRPI0509564A (pt) | derivados pirrolo(2,3-b)piridina, respectivo preparo e respectiva utilização farmacêutica como inibidores de quinases | |
| UA101643C2 (en) | 2-ALKYLAMINO-3-ARYLSULFONYL-CYCLOALCANO [e OR d] PYRAZOLO[1,5-A]PYRIMIDINES AS ANTAGONISTS OF SEROTONIN 5-HT6 RECEPTORS, PROCESS FOR THE PREPARATION AND USE THEREOF | |
| WO2008031771A3 (en) | 3-azabicyclo [4. 1. 0] heptane derivatives for the treatment of depression | |
| BR112013005967A2 (pt) | "derivados di-hidro benzoxa tiazepinas, o respectivo preparo, composições farmacêuticas e utilização como moduladores dos receptores ampa". | |
| GT200600298A (es) | Derivados de n-[(4,5-difenilpirimidin-2-il)metil] amina, su preparacion y su aplicacion en terapeutica |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B11E | Dismissal acc. art. 34 of ipl - requirements for examination incomplete | ||
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
| B07B | Technical examination (opinion): publication cancelled [chapter 7.2 patent gazette] |
Free format text: ANULADA A PUBLICACAO CODIGO 7.5 NA RPI NO 2494 DE 23/10/2018 POR TER SIDO INDEVIDA. |
|
| B07B | Technical examination (opinion): publication cancelled [chapter 7.2 patent gazette] |
Free format text: ANULADA A PUBLICACAO CODIGO 7.4 NA RPI NO 2437 DE 19/09/2017 POR TER SIDO INDEVIDA, UMA VEZ QUE O PEDIDO FOI ARQUIVADO (DESPACHO 11.5, SEM PETICIONAMENTO DE RECURSO ADMINISTRATIVO) EM 18/04/2017 |
|
| B11T | Dismissal of application maintained [chapter 11.20 patent gazette] |